Dr. Sartor on Significance of Radium-223 for Community Oncologists

Oliver Sartor, MD
Published: Wednesday, Sep 16, 2015



Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

This is the first time community oncologists will have access to an alpha particle-emitting radioactive therapeutic agent, said to be a novel concept, Sartor explains. Also, radium-223 is known as a bone-targeted agent that can prolong survival in patients with castration-resistant prostate cancer. It has yet to be determined whether it will have similar effects in other patient populations.

Radium-223 is a well-tolerated agent, Sartor says, with minimal toxicities that include diarrhea and thrombocytopenia.

SELECTED
LANGUAGE


Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

This is the first time community oncologists will have access to an alpha particle-emitting radioactive therapeutic agent, said to be a novel concept, Sartor explains. Also, radium-223 is known as a bone-targeted agent that can prolong survival in patients with castration-resistant prostate cancer. It has yet to be determined whether it will have similar effects in other patient populations.

Radium-223 is a well-tolerated agent, Sartor says, with minimal toxicities that include diarrhea and thrombocytopenia.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x